SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
1-Year Return
18.59%
This Quarter Return
+5.52%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.07B
AUM Growth
-$308M
(-13%)
Cap. Flow
-$298M
Cap. Flow
% of AUM
-14.38%
Top 10 Holdings %
Top 10 Hldgs %
38.29%
Holding
115
New
23
Increased
36
Reduced
14
Closed
20
Top Buys
| 1 |
Elevance Health
ELV
|
$58.1M |
| 2 |
Amazon
AMZN
|
$57.8M |
| 3 |
Yum! Brands
YUM
|
$52.3M |
| 4 |
Royalty Pharma
RPRX
|
$38.6M |
| 5 |
89bio
ETNB
|
$33.7M |
Top Sells
| 1 |
Otis Worldwide
OTIS
|
$102M |
| 2 |
Tapestry
TPR
|
$83M |
| 3 |
Las Vegas Sands
LVS
|
$78.1M |
| 4 |
Union Pacific
UNP
|
$56.3M |
| 5 |
AT&T
T
|
$54.3M |
Sector Composition
| 1 | Healthcare | 54.01% |
| 2 | Consumer Discretionary | 14.68% |
| 3 | Technology | 7.64% |
| 4 | Communication Services | 6.4% |
| 5 | Consumer Staples | 5.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
89bio
ETNB
$1.32B
| $33.7M | 1.42% |
+2,210,536
| New | +$33.7M |
|
|
MRNS
27
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $33.3M | 1.41% |
4,831,261
+8,266
| +0.2% | +$57K |
|
28
Sutro Biopharma
STRO
$89.9M
| $26.3M | 1.11% |
5,689,086
+123,987
| +2% | +$573K |
|
29
Fidelity National Information Services
FIS
$35.9B
| $25.5M | 1.08% |
469,110
-223,895
| -32% | -$12.2M |
|
|
XYZ
30
Block, Inc.
XYZ
$45.7B
| $25.2M | 1.07% |
367,440
-476,863
| -56% | -$32.7M |
|
31
Pinterest
PINS
$25.8B
| $24.7M | 1.05% |
+907,560
| New | +$24.7M |
|
32
Ultragenyx Pharmaceutical
RARE
$3.07B
| $24.7M | 1.04% |
616,480
-200,691
| -25% | -$8.05M |
|
33
Starbucks
SBUX
$97.1B
| $24.2M | 1.02% |
232,761
-215,280
| -48% | -$22.4M |
|
34
Kezar Life Sciences
KZR
$29.8M
| $21.6M | 0.91% |
688,759
+338,333
| +97% | +$10.6M |
|
35
Warner Bros
WBD
$30B
| $21.5M | 0.91% |
+1,425,726
| New | +$21.5M |
|
36
PayPal
PYPL
$65.2B
| $20.1M | 0.85% |
+264,218
| New | +$20.1M |
|
37
Capital One
COF
$142B
| $20M | 0.84% |
+207,600
| New | +$20M |
|
38
Cogent Biosciences
COGT
$1.82B
| $19.6M | 0.83% |
1,819,693
+8,297
| +0.5% | +$89.5K |
|
39
Goldman Sachs
GS
$223B
| $18.9M | 0.8% |
+57,635
| New | +$18.9M |
|
40
Cencora
COR
$56.7B
| $17.8M | 0.75% |
111,458
-13,200
| -11% | -$2.11M |
|
41
KalVista Pharmaceuticals
KALV
$796M
| $15.6M | 0.66% |
1,983,179
+910,877
| +85% | +$7.16M |
|
42
Fulcrum Therapeutics
FULC
$414M
| $14.8M | 0.62% |
5,177,710
+902,907
| +21% | +$2.57M |
|
43
Alvotech
ALVO
$2.6B
| $12.9M | 0.54% |
1,000,000
| – | – |
|
44
Wells Fargo
WFC
$253B
| $12.6M | 0.53% |
+335,875
| New | +$12.6M |
|
45
Marvell Technology
MRVL
$54.6B
| $12.5M | 0.53% |
+289,300
| New | +$12.5M |
|
46
Match Group
MTCH
$9.18B
| $11.4M | 0.48% |
+296,801
| New | +$11.4M |
|
47
Oric Pharmaceuticals
ORIC
$1.06B
| $10.8M | 0.46% |
1,902,643
| – | – |
|
48
Agios Pharmaceuticals
AGIO
$2.09B
| $10.4M | 0.44% |
454,000
-231,772
| -34% | -$5.32M |
|
49
PepGen
PEPG
$45.9M
| $10.1M | 0.43% |
828,087
| – | – |
|
50
EyePoint Pharmaceuticals
EYPT
$966M
| $9.98M | 0.42% |
3,394,897
+47,000
| +1% | +$138K |
|